My lab is focusing on reprogramming T and NK cells to maximize their antitumor function in the context of an immunosuppressive tumor microenvironment (TME). Using the genome-editing platform we developed, we are investigating the interaction of reprogrammed T cells with the TME in relevant immunocompetent and humanized mouse models to ultimately design T cells overcoming the TME. To prevent relapses, we are also developing new receptor architectures that improve CAR T cell persistence and increase their sensitivity to low antigen density.